A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT05934513 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions

DRUG: GFH009

Sponsor

Genfleet Therapeutics (Shanghai) Inc.